Novartis, Antisoma Enter Deal: $100M Near-Term For AS1404 April 20, 2007 Roche's loss became Novartis' gain - maybe - in the increasingly competitive cancer space occupied by vascular disrupting agents (VDAs), where Antisoma plc holds a strong position. (BioWorld Today)Read More
Financings roundup: Masimo files for up to $150M IPO; Reliant in $15 million 'E' round April 20, 2007 By Holland Johnson
RSS